Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia
Avanzanite Bioscience's partner, Agios Pharmaceuticals, has received European Commission approval for PYRUKYND® (mitapivat) for treating anemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia in adults. Avanzanite will be responsible for commercializing and distributing PYRUKYND in Europe as per their exclusive agreement with Agios. This approval marks the second indication for PYRUKYND in the EU, offering a new oral treatment option for thalassaemia patients regardless of genotype or transfusion burden.
Agios Pharmaceuticals Receives EU Approval for PYRUKYND® as First Medicine for Thalassemia Treatment in Adults
Agios Pharmaceuticals announced that the European Commission has granted marketing authorization for PYRUKYND (mitapivat), making it the first and only approved medication in the EU for adults with both transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassemia. This approval expands PYRUKYND's market presence, which already includes the U.S., Saudi Arabia, and the UAE, and is based on positive results from its Phase 3 clinical trials. Agios will partner with Avanzanite Bioscience B.V. for distribution in Europe to address the significant needs of thalassemia patients.
Avanzanite Bioscience's partner Agios announces Pyrukynd® (mitapivat) approval in EU
Avanzanite Bioscience's partner Agios Pharmaceuticals announced that Pyrukynd® (mitapivat) has received approval in the European Union for adults with thalassemia. This regulatory milestone follows earlier news of the drug's EU approval, reinforcing its therapeutic potential for hemolytic anemias. Agios Pharmaceuticals is also pursuing accelerated approval for mitapivat in sickle cell disease and developing other therapies for rare diseases.
A Look At Agios Pharmaceuticals (AGIO) Valuation After Mitapivat FDA Filing And New Clinical Data Milestones
Agios Pharmaceuticals (AGIO) recently filed a supplemental New Drug Application for accelerated FDA approval of mitapivat in sickle cell disease and is set to present new trial data. Despite regulatory progress, the stock has shown mixed signals, with a 30-day gain but a 1-year decline. Simply Wall St's analysis suggests the stock is undervalued with a fair value of $41.13 compared to its current $28.50, driven by anticipated revenue growth from PYRUKYND, though it also notes a rich sales multiple compared to industry peers.
How Investors Are Reacting To Agios Pharmaceuticals (AGIO) FDA Bid For Mitapivat In Sickle Cell Disease
Agios Pharmaceuticals has filed a supplemental New Drug Application (sNDA) with the FDA for accelerated approval of mitapivat to treat sickle cell disease, supported by Phase 2/3 RISE UP data and an agreed-upon confirmatory trial. This move could solidify Agios's position as a rare-disease company focused on red blood cell metabolism. Investors are closely watching the accelerated approval decision and the success of the transfusion burden confirmatory trial, as the company's future remains highly dependent on this single asset.
Agios Pharmaceuticals (Nasdaq:AGIO) - Stock Analysis
Agios Pharmaceuticals recently submitted a supplemental New Drug Application (sNDA) to the FDA for accelerated approval of mitapivat in sickle cell disease, supported by positive data from the RISE UP Phase 2 and 3 trials. The company's financials show it is currently unprofitable, with a net loss of US$99.1m in Q1 2026, though revenue beats analyst expectations and is forecast to grow significantly. Despite competitive pressures and initial mixed trial results, analyst sentiment remains varied, with some optimism around regulatory catalysts for mitapivat in sickle cell disease and thalassemia.
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
Agios Pharmaceuticals has submitted a supplemental new drug application (sNDA) to the FDA for accelerated approval to expand the label of its lead drug, mitapivat, for the treatment of sickle cell disease (SCD). This submission follows alignment with the FDA on a confirmatory study designed to support this approval, which will assess mitapivat's ability to reduce transfusion burden in SCD patients. The company anticipates receiving notice of the sNDA filing acceptance and review timeline in the third quarter of 2026.
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
Agios Pharmaceuticals has submitted a supplemental new drug application (sNDA) to the FDA for accelerated approval of its drug mitapivat to treat sickle cell disease (SCD). The company expects to hear about the sNDA's acceptance and review timeline in Q3 2026. This application follows discussions with the FDA about a confirmatory study, which is necessary to convert potential accelerated approval to traditional approval, despite mixed results from an earlier Phase III study.
Truist Financial Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Truist Financial analyst Gregory Renza has maintained a Buy rating on Agios Pharmaceuticals (AGIO.US). The analyst has a success rate of 47.1% and an average return of 17.8% over the past year, according to TipRanks data. This information is intended for informational purposes only and not as an investment recommendation.
Agios submits application for mitapivat in sickle cell disease
Agios Pharmaceuticals has submitted a supplemental New Drug Application to the FDA for accelerated approval of mitapivat to treat sickle cell disease. This submission is supported by data from the RISE UP Phase 2 and Phase 3 trials, which demonstrated significant improvement in hemoglobin response and reductions in pain crises for patients receiving mitapivat. The company expects a filing acceptance notification and review timeline in Q3 2026, with full trial results to be presented in June 2026.
Agios submits application for mitapivat in sickle cell disease By Investing.com
Agios Pharmaceuticals Inc. has submitted a supplemental New Drug Application to the U.S. FDA for accelerated approval of its drug mitapivat for sickle cell disease. The submission, based on positive data from Phase 2 and 3 trials, follows an agreement with the FDA for a confirmatory clinical trial. Despite a recent stock decline, InvestingPro analysis suggests the company is undervalued, boasts sales growth, and maintains a strong financial position.
Agios Pharmaceuticals Submits Supplemental New Drug Application for Mitapivat in Sickle Cell Disease Following FDA Agreement on Confirmatory Trial
Agios Pharmaceuticals has submitted a supplemental New Drug Application (sNDA) to the FDA for accelerated approval of mitapivat to treat sickle cell disease. This follows an agreement with the FDA on a confirmatory clinical trial, which will involve approximately 159 patients to demonstrate mitapivat's effectiveness in reducing transfusion burden. Data from the RISE UP Phase 3 trial showed significant improvements in hemoglobin and reduced complications, positioning mitapivat to be the first PK activator approved for sickle cell disease in the U.S.
Agios presents mitapivat data at European hematology congress
Agios Pharmaceuticals announced it will present new data on its drug mitapivat at the 31st European Hematology Association (EHA) Congress, including detailed results from its RISE UP Phase 3 trial in sickle cell disease and long-term data from the ENERGIZE Phase 3 trial in thalassemia. The company also reported strong Q1 2026 financial results, with EPS and revenue exceeding analyst expectations, driven by the successful launch of AQVESME and a submitted supplemental New Drug Application for mitapivat in sickle cell disease. Despite a recent stock decline, analysts project 20% revenue growth for the current year, and InvestingPro analysis suggests the stock is undervalued.
New pill for sickle cell moves to FDA review, aims to cut transfusions
Agios Pharmaceuticals has submitted a supplemental New Drug Application (sNDA) to the FDA for accelerated approval of mitapivat, an oral PK activator, for sickle cell disease. This submission is supported by positive data from the RISE UP Phase 2/3 trials, which indicated improved hemoglobin and reduced hemolysis, as well as benefits in pain crises, hospitalizations, and fatigue for responders. The company anticipates FDA acceptance of the filing in Q3 2026, following agreement with the FDA on a required 52-week confirmatory trial.
47,414 Shares in Agios Pharmaceuticals, Inc. $AGIO Acquired by State of New Jersey Common Pension Fund D
The State of New Jersey Common Pension Fund D acquired 47,414 shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), valued at approximately $1.29 million, initiating a new position in the company during the fourth quarter. This move comes as Agios Pharmaceuticals reported better-than-expected quarterly results, with EPS of -$1.69 against an expected -$1.81 and a revenue increase of 137.7% year-over-year. Despite mixed Wall Street ratings and ongoing insider selling, institutional investors like Creative Planning and Assetmark Inc. also increased their stakes in the biopharmaceutical company.
Price-Driven Insight from (AGIO) for Rule-Based Strategy
This article provides a price-driven analysis for Agios Pharmaceuticals Inc. (NASDAQ: AGIO) using AI models to offer insights for rule-based trading strategies. It highlights a near-term neutral sentiment, suggests testing resistance, and outlines specific position, momentum breakout, and risk hedging strategies with detailed entry, target, and stop-loss levels. The report also includes a multi-timeframe signal analysis indicating weak sentiment in mid and long-term horizons.
Number of shareholders of Agios Pharmaceuticals, Inc. – TRADEGATE:8AP
This article provides details on the number of shareholders for Agios Pharmaceuticals, Inc. (TRADEGATE:8AP). It presents financial data, news, and community discussion links for the company on the TradingView platform. The content primarily serves as a financial data portal, indicating market status and providing links to various information categories.
Lynx1 (AGIO) discloses 5.1% stake — 3.01M shares reported
Lynx1 Capital Management and Weston Nichols have jointly reported a 5.1% beneficial ownership stake in Agios Pharmaceuticals (AGIO), totaling 3,013,949 shares of common stock. This disclosure was made via a SCHEDULE 13G SEC filing, indicating the shares are held by Lynx1 Master Fund LP with shared voting and dispositive power. The percentage calculation is based on 59,471,609 shares outstanding as of April 24, 2026.
Assessing Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Pullback
Agios Pharmaceuticals (AGIO) has experienced a significant share price pullback recently, with the stock down 22% in the past month. Despite this, a popular narrative suggests the company is 34% undervalued, estimating a fair value of $41.50 due to the potential FDA approval and commercial launch of PYRUKYND for thalassemia. However, concerns exist regarding its rich sales multiple compared to peers and the ongoing net losses.
Need To Know: Analysts Are Much More Bullish On Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Revenues
This article focuses on the significant increase in revenue forecasts for Agios Pharmaceuticals (NASDAQ:AGIO) by financial analysts. It suggests that this upward revision indicates growing optimism about the company's future performance, which could be an important factor for investors to consider. The article implies that understanding these revised expectations is crucial for evaluating AGIO's stock.
Agios Pharmaceuticals Stock Rises 11.2% on Strong Q1 2026 Aqvesme Launch and Pipeline Progress
Agios Pharmaceuticals saw its stock rise 11.2% this week following a strong Q1 2026 earnings report, driven by the successful U.S. commercial launch of Aqvesme and pipeline advancements. The company reported total revenue of $20.7 million, up from $8.7 million in Q1 2025, largely due to Aqvesme sales. Despite a setback with a competing drug in sickle cell disease, Agios is pursuing accelerated FDA approval for mitapivat in SCD and anticipates Phase 2 results for its next-generation drug, tebapivat, in the first half of 2026.
Agios Pharmaceuticals (AGIO) Is Up 11.2% After Rare Disease Launch And FDA Acceleration News - Has The Bull Case Changed?
Agios Pharmaceuticals (AGIO) saw an 11.2% increase in stock after reporting strong Q1 2026 revenue growth and advances in its rare disease pipeline. The company’s AQVESME for thalassemia launched successfully, and the FDA accelerated the timeline for mitapivat in sickle cell disease, reinforcing its focus on rare disease treatments. While these developments tie near-term revenue more closely to the mitapivat franchise, the company continues to face high operational costs and funding risks.
RBC Capital Sticks to Its Hold Rating for Agios Pharma (AGIO)
RBC Capital maintained a Hold rating on Agios Pharma (AGIO) with a $28.00 price target. This comes despite the company reporting increased quarterly revenue but also a higher net loss compared to the previous year. Corporate insider sentiment towards the stock is negative, with an increase in insider selling over the past quarter.
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2026 Earnings Call Transcript
Agios Pharmaceuticals reported strong Q1 2026 results, exceeding earnings expectations with $20.7 million in net revenues, a 138% year-over-year growth. The U.S. launch of AQVESME for thalassemia showed robust initial demand with 242 prescriptions, and the company plans to submit an sNDA for mitapivat in sickle cell disease in Q2. Agios also anticipates key Phase II data for tebapivat in both lower-risk MDS and sickle cell disease later in 2026, reinforcing its focus on rare hematology and pipeline expansion.
Truist Financial Issues Pessimistic Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price
Truist Financial has lowered its price target for Agios Pharmaceuticals (NASDAQ:AGIO) from $39.00 to $36.00, while maintaining a "buy" rating. This adjustment still implies a potential upside of 28.34% from the current stock price. Despite the positive Q1 earnings report where Agios beat EPS and revenue estimates, analysts' consensus remains "Hold" with a target of $41.56, highlighting the company's unprofitability and dependence on successful commercialization and clinical approvals.
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
Agios Pharmaceuticals (AGIO) reported a Q1 2026 loss of $1.69 per share, narrower than expected, and revenues of $20.7 million, significantly beating estimates due to strong sales of its new drug Aqvesme and continued growth in Pyrukynd. The company's stock rose 13% following the announcement, driven by the strong commercial launch momentum of its products and ongoing pipeline developments, including plans for accelerated approval of mitapivat for sickle cell disease.
AGIO SEC Filings - Agios Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms
This page provides access to Agios Pharmaceuticals Inc (AGIO) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms, enhanced with AI-powered summaries. The latest filings discuss an insider grant of RSUs and options to Director Cynthia Smith, and the registration of additional shares for the company's equity plan. These updates offer insight into the company's financial governance and capital structure.
Agios Pharmaceuticals (AGIO) Heavy EPS Loss Tests Growth‑Led Bullish Narratives Heading Into Q1 2026
Agios Pharmaceuticals (AGIO) reported a Q4 2025 revenue of $19.97 million and a basic EPS loss of $1.85, with a trailing twelve-month revenue of $54.03 million and a basic EPS loss of $7.12. Despite forecasts for 37.8% annual revenue growth, the company has persistent heavy losses, remaining unprofitable for at least the next three years. This situation challenges bullish narratives that rely on future execution and revenue growth from its rare disease pipeline, while the high Price/Sales multiple and deep losses raise skepticism among critics.
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Up on Earnings Beat
Agios Pharmaceuticals (NASDAQ:AGIO) saw its shares gap up following a better-than-expected earnings report, with the company beating both EPS and revenue estimates. Despite some insider selling to cover tax obligations, institutional investors like Goldman Sachs increased their stakes. Analyst sentiment is mixed, with an average "Hold" rating, though several firms revised their price targets.
Agios Pharmaceuticals Releases Q1 2026 Financial Results
Agios Pharmaceuticals reported a narrower-than-expected loss for Q1 2026, with revenue of $20.7 million, exceeding analyst estimates. The company's Mitapivat franchise was a key driver of growth, contributing $18.8 million in revenue. Despite a wider net loss compared to the previous year, Wall Street analysts maintain a bullish outlook due to the company's strong commercial execution and pipeline potential.
Agios Pharmaceuticals (NASDAQ: AGIO) grows Q1 2026 sales while funding deep rare-disease pipeline
Agios Pharmaceuticals reported a rise in Q1 2026 product revenue to $20.7 million, up from $8.7 million in the prior year, driven by the U.S. launch of AQVESME™ for thalassemia and increased PYRUKYND® sales. Despite revenue growth, the company's net loss widened to $99.1 million due to increased research and development spending on its rare-disease pipeline. Agios maintains a strong cash position of $1.0 billion, which is expected to fund operations for at least 12 months as it progresses clinical trials for several product candidates, including mitapivat for sickle cell disease.
Earnings call transcript: Agios Q1 2026 earnings soar past expectations
Agios Pharmaceuticals reported robust financial results for Q1 2026, with EPS of -$1.69 against a forecast of -$1.81 and revenue of $18.8 million, significantly exceeding the $13.91 million expectation. This outperformance was primarily driven by the successful commercial launch of AQVESME in thalassemia, leading to a 4.88% premarket stock price increase and reflecting strong investor confidence. The company also provided positive updates on its pipeline, including plans for an sNDA submission for mitapivat in sickle cell disease and upcoming phase II data for tebapivat in MDS and sickle cell disease.
Agios Pharmaceuticals Inc reports results for the quarter ended March 31 - Earnings Summary
Agios Pharmaceuticals Inc has released its earnings summary for the quarter that ended on March 31. The report contains the financial results for the specified period. This brief announcement is provided by Refinitiv.
Agios Pharmaceuticals Releases Q1 2026 Financial Results
Agios Pharmaceuticals reported a narrower-than-expected loss in Q1 2026, with a loss of $1.69 per share against an anticipated $1.84, representing an 8.2% improvement. Revenue surged by 137.8% to $20.7 million, primarily driven by its Mitapivat franchise. Despite strong revenue growth, the net loss widened to $99.1 million due to continued investments in development and commercialization.
Agios Pharmaceuticals: Q1 Earnings Snapshot
Agios Pharmaceuticals Inc. (AGIO) reported a first-quarter loss of $99.1 million, or $1.69 per share, which was better than analysts' expectations of a $1.81 per share loss. The company also surpassed revenue forecasts, posting $20.7 million against an expected $13.8 million. Despite beating estimates, the company's shares have seen a decline of nearly 9% year-to-date and 16% over the last 12 months.
Earnings Flash (AGIO) Agios Pharmaceuticals, Inc. Reports Q1 Revenue $20.7M, vs. FactSet Est of $13.3M
Agios Pharmaceuticals, Inc. (AGIO) reported Q1 revenue of $20.7 million, significantly exceeding FactSet's estimated $13.3 million. This positive revenue surprise comes despite the company reporting a wider Q1 loss. The company's lead product candidate, PYRUKYND (Mitapivat), is being evaluated for various hemolytic anemias and is contributing to its financial performance.
Agios (NASDAQ: AGIO) doubles mitapivat revenue and funds 2026 pipeline catalysts
Agios Pharmaceuticals reported strong mitapivat revenue growth in Q1 2026 due to the U.S. launch of AQVESME, with worldwide net revenues reaching $20.7 million, more than double the previous year. Despite increased R&D and SG&A expenses leading to a deeper net loss of $99.1 million, the company maintains a robust cash position of $1.0 billion to fund pipeline catalysts. Key upcoming milestones include a supplemental NDA filing for mitapivat in sickle cell disease and Phase 2 readouts for tebapivat in myelodysplastic syndromes and sickle cell disease, signaling significant advancements in its rare hematology pipeline.
BofA Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO)
BofA analyst Alec Stranahan reaffirmed a Buy rating for Agios Pharmaceuticals (AGIO) but reduced the price target to $41 from $44 due to competitive risks from Novo Nordisk's etavopivat for sickle cell disease. H.C. Wainwright also lowered its price target on AGIO to $50 from $65 for similar reasons, as Novo Nordisk's once-daily drug is seen as a strong competitor to Agios's twice-daily mitapivat. Despite these challenges, Agios Pharmaceuticals, which develops therapeutics in cellular metabolism, is still considered among the best oversold small-cap stocks.
BofA Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO)
BofA analyst Alec Stranahan reaffirmed a Buy rating for Agios Pharmaceuticals (AGIO) but reduced its price target to $41 from $44 due to regulatory risks posed by Novo Nordisk's competing sickle cell disease drug, etavopivat. H.C. Wainwright also lowered its price target on AGIO to $50 from $65, citing the success of Novo Nordisk's Phase 3 HIBISCUS trial for etavopivat, which is expected to reduce the commercialization potential of Agios's mitapivat. Despite competitive challenges, AGIO is still considered a strong oversold small-cap stock.
BofA Reaffirms Buy Rating for Agios Pharmaceuticals (AGIO)
BofA analyst Alec Stranahan reaffirmed a Buy rating for Agios Pharmaceuticals (AGIO) but reduced the price target to $41 from $44 due to regulatory risks from Novo Nordisk's etavopivat. H.C. Wainwright analyst Emily Bodnar also lowered her price target from $65 to $50, citing the success of Novo Nordisk's HIBISCUS trial, which is expected to impact the commercial potential of Agios's mitapivat. Despite these competitive pressures, Agios (AGIO) is still considered an oversold small-cap stock.
Q3 2025 Agios Pharmaceuticals Inc Earnings Call Transcript
Agios Pharmaceuticals Inc. (AGIO) reported a 44% increase in net revenue for Q3 2025 and announced its first global regulatory approval for pyrokine in Saudi Arabia. Despite a robust balance sheet of $1.3 billion, the company faces delays with the FDA for pyrokine thalassemia and increased R&D expenses, impacting launch timelines and profitability.
10 Oversold Small Cap Stocks to Buy Now
This article identifies Agios Pharmaceuticals Inc. (NASDAQ: AGIO) as one of the 10 oversold small-cap stocks to consider buying. Analyst ratings from BofA and H.C. Wainwright maintained "Buy" ratings despite downward price target revisions due to competitive risks from Novo Nordisk's etavopivat for sickle cell disease. Agios Pharmaceuticals is engaged in discovering and creating therapeutics focusing on cellular metabolism, with products like PYRUKYND (mitapivat).
Agios Pharmaceuticals (NASDAQ: AGIO) outlines 2026 virtual meeting, director elections and plan amendment
Agios Pharmaceuticals (NASDAQ: AGIO) will hold its 2026 Annual Meeting of Stockholders virtually on June 18, 2026, at 9:00 a.m. Eastern Time. Key agenda items include the election of three Class I directors, an advisory vote on executive compensation, approval of an amendment to the 2023 Stock Incentive Plan to increase available shares, and the ratification of PricewaterhouseCoopers LLP as the independent auditor. The company emphasizes its commitment to corporate governance, ESG initiatives, and a pay-for-performance compensation philosophy for its executives.
Do Agios Pharmaceuticals’ (AGIO) EPS Revisions Hint At A Turning Point In Its Investment Story?
Agios Pharmaceuticals (AGIO) is preparing to report its March 2026 quarterly results with expected losses but higher year-over-year revenue, and analysts have revised EPS estimates upward. The company's investment narrative hinges on its mitapivat drug for rare blood disorders and its recent plan to seek accelerated FDA approval for sickle cell disease. Despite potential short-term losses, the long-term revenue opportunity is significant, though concerns about hepatocellular injury risk and drug dependence remain.
Do Agios Pharmaceuticals’ (AGIO) EPS Revisions Hint At A Turning Point In Its Investment Story?
Agios Pharmaceuticals is facing a critical juncture as analysts have revised EPS estimates upward despite expecting a quarterly loss for March 2026. The company's investment narrative heavily relies on the success of mitapivat for rare blood disorders, with a recent focus on seeking accelerated FDA approval for sickle cell disease. While projections show significant revenue and earnings growth by 2029, concerns about hepatocellular injury risk and the narrow drug dependence could influence investor decisions.
A Look At Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Volatility
Agios Pharmaceuticals (AGIO) is currently trading at US$26.72, below the average analyst price target, despite recent share price swings. The market narrative suggests it's 36% undervalued with a fair value of $41.50, driven by the anticipated FDA approval and commercial launch of PYRUKYND. However, the company's high P/S ratio of 29x, compared to the industry average of 11.7x, indicates potential over-optimism regarding future growth and product success.
Agios Pharmaceuticals (AGIO) Projected to Post Quarterly Earnings on Wednesday
Agios Pharmaceuticals (AGIO) is projected to announce its Q1 2026 earnings before market open on Wednesday, April 29th, with analysts expecting an EPS loss of ($1.82) and revenue of approximately $13.91 million. The stock has experienced competitive pressure and a price drop following Novo's late-stage PKR activator win, which challenged Agios's mitapivat program. The company currently holds an average analyst rating of "Hold" with a consensus target price of $41.78.
Earnings Preview: Agios Pharmaceuticals (AGIO) Q1 Earnings Expected to Decline
Agios Pharmaceuticals (AGIO) is projected to report a year-over-year decline in Q1 earnings, despite an expected increase in revenues. While the consensus estimate predicts a loss of $1.81 per share, the Zacks Earnings ESP suggests a slightly more bearish outlook, making a definitive earnings beat difficult to predict. Investors are advised to consider other factors alongside these estimates.
Agios Stock Sinks 23% as NVO's PKR Activator Meets Goal in SCD Study
Agios Pharmaceuticals (AGIO) saw its stock drop by 23% following an announcement from Novo Nordisk (NVO) regarding positive Phase III trial results for its sickle cell disease (SCD) drug, etavopivat. This news raises competitive concerns for Agios, which is developing a similar drug, mitapivat, for SCD. Novo Nordisk's etavopivat met its primary endpoints, setting a high bar for efficacy and potentially complicating Agios's path to accelerated approval for mitapivat in the SCD market.
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Down - Here's Why
Agios Pharmaceuticals (NASDAQ:AGIO) saw its shares gap down on Monday, opening at $29.58 after closing at $35.14, with significant trading volume. Despite this drop, analysts have issued several "buy" and "outperform" ratings, and the consensus price target on MarketBeat remains a "Hold" at $42.67. Insider sales were primarily for tax obligations, while institutional investors significantly increased their positions, suggesting mixed sentiment around the biopharmaceutical company.
